December 27, 2024 09:11 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
I have lost a mentor and guide: Rahul Gandhi writes on Manmohan Singh's demise | Manmohan Singh left strong imprint on our economic policy over years: PM Modi | A rare leader who spoke softly but achieved monumental strides: Gautam Adani mourns Manmohan Singh's death | Instagram influencer and freelance RJ Simran Singh dies by suicide in Gurugram | Anna University sexual assault case: Accused is a DMK worker, claims BJP's Annamalai | Celebrities too responsible for crowd control: Telangana CM Revanth Reddy to Telugu filmdom amid Pushpa 2 stampede row | Boat capsizes off Calangute Beach in Goa; 1 killed, 20 rescued | Canada announces change to immigration system, likely to impact Indians seeking permanent residence | Azerbaijan Airlines tragedy: 32 passengers rescued, flight attempted several emergency landing before crashing | Man sets himself on fire near Parliament building; locals, police rush him to hospital
Hetero’s Covid-19 oral drug 'Paxlovid' to receive WHO prequalification

Hetero’s Covid-19 oral drug 'Paxlovid' to receive WHO prequalification

Dec 26, 2022, at 08:21 pm

Hyderabad/Kolkata: Hetero, a pharmaceutical company, on Monday announced the receipt of World Health Organization Prequalification of Medicines Program (WHO PQ) approval for its generic version of COVID-19 oral antiviral treatment candidate nirmatrelvir.